SS
NRXP icon

Steve Schonfeld’s NRX Pharmaceuticals NRXP Stock Holding History

Steve Schonfeld’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,876
Closed -$42.3K – 2877
2026
Q1 		$42.3K Buy
+19,876
New +$40.1K ﹤0.01% 1991
2022
Q1 		– Sell
-2,810
Closed -$135K – 2809
2021
Q4 		$135K Buy
+2,810
New +$203K ﹤0.01% 1836

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Steve Schonfeld's NRXP Position: Q2 2026 in Review

Steve Schonfeld sold out of NRX Pharmaceuticals (NRXP) in Q2 2026, closing a stake of 19,876 shares — an estimated $42.3K sold.

Steve Schonfeld first reported a position in NRXP in Q4 2021 and held it in 2 quarters. The position peaked at $135K in Q4 2021. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Steve Schonfeld reported no remaining NRX Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 19,876 NRX Pharmaceuticals shares in Q2 2026, an estimated $42.3K.
  • Steve Schonfeld first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Steve Schonfeld's NRX Pharmaceuticals position peaked at $135K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.